Here are the 10-K annual reports from Alaunos Therapeutics, Inc. (TCRT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow TCRT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TCRT filings page.
Alaunos Therapeutics, Inc. filed an amendment to its annual report to add Part III information that had been omitted from the original Form 10-K. The amendment details the company’s board and governance structure, executive and director compensation, and security ownership of key stockholders and management.
The filing confirms a four‑member board, led by CEO and chair Holger Weis, and describes committee membership and independence under Nasdaq rules. It also outlines employment and consulting agreements, equity incentive plans, ownership concentrations among major holders, and audit fees paid to Cherry Bekaert LLP, without changing previously reported financial statements.
Alaunos Therapeutics, Inc. reports a strategic pivot to an early-stage, oral small‑molecule obesity and metabolic disorders program while warning of severe financial strain. For 2025, the company recorded a net loss of $4.2 million and an accumulated deficit of $924.6 million as of December 31, 2025.
Cash and cash equivalents were about $1.4 million, which management expects will fund operations only into the second quarter of 2026, raising substantial doubt about continuing as a going concern. Stockholders’ equity was $2.2 million, below Nasdaq’s $2.5 million equity requirement, creating renewed delisting risk.
The lead obesity candidate, ALN1003, has shown dose-dependent weight loss and metabolic improvements in diet‑induced obesity mouse models but remains in preclinical, non‑GLP studies with significant scientific, regulatory, financing, and execution risks. The company now has only one full-time employee and relies heavily on consultants, has identified a material weakness in internal control due to limited personnel, and highlights the possibility that failure to fund or advance the program could lead the board to consider dissolution and liquidation.